Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Treatment cessation using venetoclax-based therapy for older patients with AML

Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia, talks on the combination of venetoclax with low-dose therapy as a new standard of care for older patients with acute myeloid leukemia who have not received prior treatment, in particular discussing whether it is necessary to continue this therapy combination until disease progression. Prof. Wei describes the findings of a study which compared the outcomes of patients elected to cease therapy, and those who didn’t, reporting that no significant difference in progression-free survival or overall survival was observed between the two groups. Prof. Wei also comments on measurable residual disease findings and the impact of biomarkers, such as NPM1, IDH2 and SRSF2, on patient outcomes. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Disclosures

Andrew Wei, MBBS, PhD, has received research grants from Abbvie, Amgen, AstraZeneca, Celgene/BMS, Novartis, Servier and F. Hoffmann-La Roche; has received honoraria from Abbvie, Amgen, Astellas, AstraZeneca, Celgene/BMS, Genentech, Janssen, MacroGenics, Novartis, Pfizer, and Servier; has participated in advisory boards for Abbvie, Amgen, Astellas, AstraZeneca, Celgene/BMS, Genentech, Janssen, MacroGenics, Novartis, Pfizer, and Servier; has participated in speakers bureau for Novartis, Abbvie and Celgene/BMS, has participated in consultancy work for Servier; is a former employee of the Walter and Eliza Hall Institute, and is eligible for a fraction of the royalty stream related to Venetoclax.